Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in … – Business Wire (press release)
Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in …Business Wire (press release)BUSINESS WIRE)–Kite Pharma, Inc., (Nasdaq:KITE) today announced two plenary presentations of positive dat… Continue reading
